[ad_1]
Planegg/Martinsried, August 16, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be participating in the H.C. Wainwright Immune Cell Engager Virtual Conference on August 17, 2023.
Members of Medigene’s management team will participate in a fireside chat and will be available for virtual one-on-one meetings with registered investors.
— end of press release —
About Medigene
Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell therapies to effectively eliminate cancer. Its end-to-end technology platform, built on multiple proprietary and exclusive product development and product enhancement technologies, allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Medigene
Pamela Keck
Phone: +49 89 2000 3333 01
E-mail: [email protected]
LifeSci Advisors
Sandya von der Weid
Phone: +41 78 680 05 38
E-mail: [email protected]
In case you no longer wish to receive any information about Medigene, please inform us by e-mail ([email protected]). We will then delete your address from our distribution list.
[ad_2]
Source link
